Bio-Techne

TECH

Market cap $9.62B

QUEBEC CITY--(BUSINESS WIRE)-- #cellpainting--Saguaro Biosciences, a pioneer in non-toxic live cell reagents for enhanced drug insights, announces a new distribution agreement with Bio-Techne Corporation (NASDAQ:TECH), a global provider of life science tools, reagents and diagnostic products. The partnership will leverage Bio-Techne's extensive international sales and marketing channels to provide researchers worldwide with better access to Saguaro's portfolio of non-toxic, wash-free dyes. This strategic allia.

MINNEAPOLIS , Oct. 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, November 5, 2025, at 8:00 a.m. CST to review its first quarter fiscal 2026 financial results.

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR (GMAB) and Techne (TECH). But which of these two stocks is more attractive to value investors?

Grants Bio-Techne expanded commercial rights to develop a portfolio of genetics products beyond the recently launched AmplideX® Nanopore Carrier Plus Kit Establishes a framework to define and propose future portfolios Extends collaboration through 2032, reinforcing Bio-Techne's diagnostics growth strategy and strengthening relationship with Oxford Nanopore Technologies MINNEAPOLIS , Oct. 9, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced a significant enhancement to its agreement with Oxford Nanopore Technologies (LSE: ONT). The expanded agreement broadens Bio-Techne's ability to develop a portfolio of genetic products on Oxford Nanopore Technologies platforms and extends the collaboration through 2032.

TECH drives growth via acquisitions, international strength and innovation. However, it faces macro pressures and rising competition.

TECH shares rise as advances in RNAscope and COMET spotlight new roles in lymphoid malignancy diagnostics.

RNAscope™ technology and the Lunaphore COMET™ enable simultaneous RNA and protein detection on the same tissue section Technologies support spatial multiomic analysis and deeper insights for pathology workflows Research highlights potential role in clinical utility workflows for lymphoid malignancies and B-cell clonality MINNEAPOLIS , Sept. 26, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced new advancements in its spatial biology portfolio for the RNAscope™ ISH technology and the Lunaphore COMET™.

Company advances transition to renewable electricity and sets a pathway to science-based emissions reductions MINNEAPOLIS , Sept. 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today released its 2025 Corporate Sustainability Report, underscoring the company's commitment to advancing human health while protecting the planet.

Bio-Techne Corporation (NASDAQ:TECH ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT Company Participants James Hippel - Executive VP of Finance & CFO Presentation Unknown Analyst All right. Thank you, everyone, for joining today.

Bio-Techne Corporation (NASDAQ:TECH ) Baird Global Healthcare Conference 2025 September 9, 2025 9:05 AM EDT Company Participants James Hippel - Executive VP of Finance & CFO Conference Call Participants Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Presentation Catherine Ramsey Senior Research Analyst Catherine Schulte.